From Experimental Pilots to Guardrailed Enterprise AI
Enterprise AI in life sciences is shifting from experimental pilots to production systems that must withstand regulatory scrutiny. Organisations are eager to automate pharmacovigilance, clinical documentation, and quality workflows, yet they face an enterprise AI compliance paradox: the most powerful models are probabilistic, while regulated processes demand deterministic behaviour and full traceability. This tension has slowed regulated industry AI deployments to a crawl. Vendors are now responding by embedding compliance directly into AI workflows rather than treating it as an afterthought. Accenture’s backing of Iridius, Celonis’ acquisition of Ikigai Labs, and the US FDA’s clearance of Glooko’s cloud-based insulin dosing platform all illustrate a new pattern. Instead of focusing only on smarter algorithms, the emphasis is moving toward AI healthcare infrastructure and decision intelligence platforms that can encode policies, surface audit trails, and keep a human firmly “in the lead” for high‑stakes decisions.
Accenture and Iridius: Turning Regulations into Machine-Readable Guardrails
Accenture’s investment in Iridius targets the core bottleneck in regulated industry AI: reliably translating sprawling rule books into operational logic. Life sciences companies juggle thousands of SOPs, policies, and work instructions, plus external regulations that vary widely. Iridius tackles this by building a knowledge engine that ingests these documents and converts them into structured, machine‑readable logic that can be embedded inside automated workflows. The company frames this as “auto policy execution”: first transform regulations into compliance logic, then orchestrate workflows that must follow those rules, and finally generate continuous evidence so every AI action is traceable and auditable. Crucially, Iridius also defines boundaries where AI agents must stop, escalate, and wait for human review. This “human in the lead” pattern lets organisations exploit AI speed while maintaining deterministic control, offering a reusable compliance layer that can be applied across diverse use cases instead of rebuilding guardrails for every new agent.
Celonis and Ikigai Labs: Context Engines for Decision Intelligence
While Iridius focuses on encoded guardrails, Celonis is attacking another obstacle to enterprise AI compliance: lack of operational context. By acquiring Ikigai Labs, a decision intelligence specialist working with large graphical models, Celonis aims to fuse its process intelligence graph with advanced forecasting and scenario simulation capabilities. The result is a decision intelligence platform that can predict what is likely to happen, explore what‑if scenarios, and recommend what should be done, all grounded in how a company actually operates. For regulated industry AI, this context is critical. Process intelligence data provides the detailed, end‑to‑end view of workflows that AI needs to deliver reliable, repeatable outcomes instead of opaque black‑box recommendations. When paired with generative AI, this data becomes a context engine that reduces the risk of non‑compliant actions, supports auditable decision paths, and helps break down internal silos that have historically blocked enterprisewide AI adoption.
Glooko’s FDA-Cleared Cloud Platform Shows the Infrastructure Pathway
Regulators are also beginning to validate AI healthcare infrastructure, not just point solutions. Glooko’s EndoTool IV Cloud recently received US FDA clearance, positioning the cloud-based insulin dosing platform for commercial rollout across hospital settings. The system uses the same core algorithm as earlier on‑premise versions, but the new cloud model reduces the need for hospital-owned infrastructure and supports more scalable deployment. EndoTool IV Cloud supports individualised intravenous insulin dosing for critically ill patients, a high‑stakes use case where traceability and consistency are paramount. By preserving the established, trusted clinical algorithm while modernising the delivery architecture, Glooko demonstrates a viable regulatory pathway for cloud-native AI healthcare infrastructure. As the global diabetes population is projected to reach 643 million by 2030, such scalable, compliant platforms will be essential for safely extending AI‑enabled decision support across diverse clinical environments.
From Software Experiments to Compliance-Centric AI Infrastructure
Taken together, these moves signal a broader shift in enterprise AI spending from experimental software toward infrastructure designed for compliant, repeatable deployments. Instead of scattering isolated AI tools across departments, hospitals and pharmaceutical firms increasingly need shared rails: policy engines, process graphs, audit systems, and cloud platforms that standardise how AI interacts with sensitive workflows. Iridius’ auto policy execution, Celonis’ context-rich decision intelligence platform, and Glooko’s FDA-cleared cloud service represent complementary layers of this emerging stack. One encodes rules, another provides operational context, and a third proves that cloud-delivered clinical algorithms can meet regulatory expectations at scale. As these patterns mature, regulated industry AI will likely evolve from risk‑averse experimentation into a more confident, infrastructure‑driven phase—where compliance is not a brake on innovation but an embedded capability that accelerates safe adoption.